At 33 years old, Kaedi Cecala faced […] ...

Juan Uribe reached 11.7 million people within 24 hours of posting his plea for help. Now, 10 days later, the video has over ...

The U.S. Food and Drug Administration (FDA) has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), to ...

TURKU, FI / ACCESS Newswire / February 23, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies ...

A beautiful bride is making headlines after […] ...

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...

The mission at NBC's "Today" has long been to give viewers the news and information they need to start their day — along with ...

Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively ...

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its ...

CareDx, Inc. ? The Transplant Companytm, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high?value healthcare solutions ...

TURKU, FI / ACCESS Newswire / February 23, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies ...

CareDx CDNA recently announced clinical validation data supporting AlloHeme, its next-generation, blood-based monitoring test designed to predict relapses in patients with acute myeloid leukemia (AML) ...